Home › Research › Biomarkers
Sex-specific biomarkers in Alzheimer's disease progression: Framingham Heart Study
Chunyu Liu, Yi Li, Adaora Nwosu, Ting Fang Alvin Ang, Yulin Liu, Sherral Devine, Rhoda Au, P Murali Doraiswamy. Alzheimer's & dementia (Amsterdam, Netherlands), 2022-11-03
Topic: Brain imaging, connectivity and assessment
During 11 years of follow-up, women were 96% more likely than men to be diagnosed with clinical AD dementia after adjusting for age and education in the younger age group 60 to 70 years (n = 946; 95% confidence interval [CI], 1.08 to 3.56) although not in the older age group (70+) (n = 452; hazard ratio = 0.98; 95% CI, 0.68 to 1.53). Sex-differences in incident AD rates decreased with increasing levels of education. The total contribution of the biomarkers to AD risk variance was 7.6% in women and 11.7% in men. One unit (pg/ml) lower plasma Aβ42 was associated with 0.0095 unit faster memory decline in women (p = 0.0002) but not in men (p = 0.55) after adjusting for age and education. Our study suggests that both early life and later-life pathological factors may contribute to potential sex differences in incident AD.
Key findings
- During 11 years of follow-up, women were 96% more likely than men to be diagnosed with clinical AD dementia after adjusting for age and education in the younger age group 60 to 70 years (n = 946; 95% confidence interval [CI], 1.08 to 3.56) although not in the older age group (70+) (n = 452; hazard ratio = 0.98; 95% CI, 0.68 to 1.53).
- Sex-differences in incident AD rates decreased with increasing levels of education.
- The total contribution of the biomarkers to AD risk variance was 7.6% in women and 11.7% in men.
- One unit (pg/ml) lower plasma Aβ42 was associated with 0.0095 unit faster memory decline in women (p = 0.0002) but not in men (p = 0.55) after adjusting for age and education.
- Our study suggests that both early life and later-life pathological factors may contribute to potential sex differences in incident AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants1,398
- Effect size7.6%; 11.7%
- Evidence strengthModerate
How this study scored 75/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 42 of the 56 points we could judge it on, which is 75 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,398 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36348973) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 42 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 42 of the 56 points we could judge it on is 75 out of 100. |
| Total | 75 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Liu, C., Li, Y., Nwosu, A., Ang, T. F. A., Liu, Y., Devine, S., et al. (2022). Sex-specific biomarkers in Alzheimer's disease progression: Framingham Heart Study. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.12369
Vancouver
Liu C, Li Y, Nwosu A, Ang TFA, Liu Y, Devine S, et al. Sex-specific biomarkers in Alzheimer's disease progression: Framingham Heart Study. Alzheimer's & dementia (Amsterdam, Netherlands). 2022. doi:10.1002/dad2.12369. PMID: 36348973.
BibTeX
@article{liu2022-36348973,
author = {Liu, Chunyu and Li, Yi and Nwosu, Adaora and Ang, Ting Fang Alvin and Liu, Yulin and Devine, Sherral and Au, Rhoda and Doraiswamy, P Murali},
title = {{Sex-specific biomarkers in Alzheimer's disease progression: Framingham Heart Study}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2022},
doi = {10.1002/dad2.12369},
pmid = {36348973},
url = {https://doi.org/10.1002/dad2.12369}
}